Why the study?
Angiotensin II-induced myocardial hypertrophy can lead to heart failure, but the role of the proinflammatory regulator IKKε in its development was unknown.
Does IKKε deficiency attenuate the development of Angiotensin II-induced myocardial hypertrophy in mice?
Does IKKε deficiency attenuate the development of Angiotensin II-induced myocardial hypertrophy in mice?
IKKε deficiency attenuates Angiotensin II-induced myocardial hypertrophy and heart failure in mice by inhibiting MEK-ERK1/2 and p38 phosphorylation, suggesting it as a potential therapeutic target.
Hypothesis-generating for IKKε targeting in hypertrophy models; leaves open translation to human HF prevention.
I‐ κ B kinase‐ ε (IKK ε ) is a member of the IKK complex and a proinflammatory regulator that is active in many diseases. Angiotensin II (Ang II) is a vasoconstricting peptide hormone, and Ang II‐induced myocardial hypertrophy is a common cardiovascular disease that can result in heart failure. In this study, we sought to determine the role of IKK ε in the development of Ang II‐induced myocardial hypertrophy in mice. Wild‐type (WT) and IKK ε ‐knockout (IKK ε ‐KO) mice were generated and infused with saline or Ang II for 8 weeks. We found that WT mouse hearts have increased IKK ε expression after 8 weeks of Ang II infusion. Our results further indicated that IKK ε ‐KO mice have attenuated myocardial hypertrophy and alleviated heart failure compared with WT mice. Additionally, Ang II‐induced expression of proinflammatory and collagen factors was much lower in the IKK ε ‐KO mice than in the WT mice. Apoptosis and pyroptosis were also ameliorated in IKK ε ‐KO mice. Mechanistically, IKK ε bound to extracellular signal‐regulated kinase (ERK) and the mitogen‐activated protein kinase p38, resulting in MAPK/ERK kinase (MEK) phosphorylation, and IKK ε deficiency inhibited the phosphorylation of MEK‐ERK1/2 and p38 in mouse heart tissues after 8 weeks of Ang II infusion. The findings of our study reveal that IKK ε plays an important role in the development of Ang II‐induced myocardial hypertrophy and may represent a potential therapeutic target for the management of myocardial hypertrophy.
No takes yet. Share an insight, caveat, or question.
Cao et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: